Aguilar Marucco D, Veronese L, de Requena D Gonzalez, Bonora S, Calcagno A, Cavecchia I, Sinicco A, De Rosa F G, Cariti G, Di Perri G
Department of Infectious Diseases, University of Turin, Amedeo di Savoia Hospital, Corso Svizzera 164, Turin, Italy.
J Antimicrob Chemother. 2007 Mar;59(3):565-8. doi: 10.1093/jac/dkl497. Epub 2007 Jan 9.
To evaluate the early anti-HIV activity of pegylated interferon (PEG-IFN) alfa-2a and ribavirin in HIV/hepatitis C virus (HCV) co-infected patients not receiving antiretroviral therapy.
In 19 patients with baseline plasma HIV load (HIV-RNA) >1000 copies/mL treated with PEG-IFN alfa-2a and ribavirin, HIV-RNA and T-cell subsets were measured at baseline and 2, 4 and 12 weeks after initiation of anti-HCV therapy.
We observed a significant HIV-RNA decrease (>1 log(10) copies/mL) through week 12 of anti-HCV treatment. The magnitude of HIV-RNA decline was associated with baseline HIV-RNA, CD4 count and PEG-IFN weight-adjusted dose.
A significant early anti-HIV activity of PEG-IFN alfa-2a was observed. Such an effect warrants further clinical evaluation in the management of co-infected patients.
评估聚乙二醇化干扰素（PEG-IFN）α-2a和利巴韦林在未接受抗逆转录病毒治疗的HIV/丙型肝炎病毒（HCV）合并感染患者中的早期抗HIV活性。
对19例基线血浆HIV载量（HIV-RNA）>1000拷贝/mL且接受PEG-IFNα-2a和利巴韦林治疗的患者，在基线以及抗HCV治疗开始后的第2、4和12周测量HIV-RNA和T细胞亚群。
在抗HCV治疗的第12周，我们观察到HIV-RNA显著下降（>1 log(10)拷贝/mL）。HIV-RNA下降幅度与基线HIV-RNA、CD4细胞计数以及PEG-IFN体重校正剂量相关。
观察到PEG-IFNα-2a具有显著的早期抗HIV活性。这种效应值得在合并感染患者的管理中进行进一步的临床评估。
